Microbial-based therapy of cancer: A new twist to age old practice

Cancer Biology and Therapy

Volumn 3, Issue 8, 2004, Pages 708-714

  Punj, Vasu ^a   Saint Dic, Djenann ^a   Daghfal, Sharon ^a   Kanwar, J R ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Apoptosis; Microorganisms; p53; Protein protein interaction; Tumor inhibition

Indexed keywords

ANTHRACYCLINE; ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; AZURIN; BACTERIAL PROTEIN; BCG VACCINE; BLEOMYCIN; CANCER VACCINE; CUPREDOXIN; DACTINOMYCIN; DESOXYEPOTHILONE B; ENTEROTOXIN; ENTEROTOXIN A; EPOTHILONE DERIVATIVE; EXOTOXIN; EXOTOXIN A; IMMUNOLOGICAL ADJUVANT; LIPID A; LIPOTECHOIC ACID; MITHRAMYCIN; MITOMYCIN; MITOMYCIN C; PACLITAXEL; PEPTIDOGLYCAN; PROTEIN A; PROTEIN P53; RHIZOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BACTERIAL CELL; BACTERIOLYSIS; BACTERIUM; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ACTIVITY; CELL INTERACTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; GENE VECTOR; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VIVO STUDY; MELANOMA; METABOLITE; MICROORGANISM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATION REDUCTION REACTION; PROTEIN PROTEIN INTERACTION; PSEUDOMONAS AERUGINOSA; REVIEW; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; APOPTOSIS; BACTERIA; CANCER VACCINES; GENETIC VECTORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 16644387358     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.8.964     Document Type: Review

References (71)

1. Chabalgoity A, Dougan G, Mastroni P, Aspinall RJ. Live bacteria as the basis for immmuotherapies against cancer. Exper Rev Vaccine 2002; 1:495-505.
2. Pasechnik V. Microbial pathogens and apoptotic anticancer therapy. Expert Opin Investig Drugs 2000; 9:1243-56.
3. Nagorsen D, Marincola FM, Kaiser HE. Bacteria-related spontaneous and therapeutic remission of human malignancies. In vivo 2002; 16:551-6.
4. Busch W. Aus der sitzung der medicinischen Section Vvom 13 Novemebr 1867. Berl Klin Wochenschr 1868; 5:137.
5. Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysioelas. Post-graduate 1893; 8:278.
6. Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, et al. Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001; 166:5878-81.
7. Dang LH, Bettegowda D, Husao DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98:15155-60.
8. Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Natl Acad Sci 2001; 98(26):14748-50.
9. Yu J, Leung WK, Ebert MP, Leong RW, Tse PC, Chan MW, et al. Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 2002; 87:91-7.
10. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen RW. Effect of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93:1541-2.
11. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Angiostatin enhances B7.1- mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther 2001; 8:719-27.
12. Alexandrof ADA, Jackson AM, Odonnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689-94.
13. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF DeHaven JI. Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 1994; 151:21-6.
14. Morales A, Edinger D, Bruce AW. Intracavity bacillus calmette guerin in the treatment of superficial bladder tumors. J Urol 1976; 110:180-3.
15. Ratlift TL, Ritchey JK, Yuan JJ, Yuan JJ, Andriole GL, Catalona WJ. T- cell subsets required for intravesical BCG immunotherapy for blade cancer. J Urol 1993; 150:1018-23.
16. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, Oday SJ, Wanek LA, et al. Enhanced humoral immune response correlates with improved disease free and overall survival in American joint committee on cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002; 20:3242-8.
17. Fujimoto T, Odonnel MA, Szilvasi A, Yang H, Yang H. BCG plus interleukin-2 and/or granulocyte/macrophage-colony stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immuunol Immunother 1996; 42:280-4.
18. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao X, Jocham D. NK cells are essential for effective BCG immuotherapy. Int J Cancer 2001; 92:697-702.
19. Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, Kurita Taniguchi M, et al. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of innate immune system by BCG cell wall skeleton. Int Immunopharmacol 2002; 1:1559-69.
20. Shepherd FA. Alternative to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer 1997; 17:S121-36.
21. Aggarwala SS, Kirkwood JM. Adjuvant therapy of melanoma. Sem Oncol 1998; 14:302-10.
22. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of Toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003; 23:4369-76.
23. Jain KK. Proteomics-based anti-cancer drug discovery and development. Technol Cancer Res Treat 2002; 1:219-20.
24. Paglia P, Guzman CA. Keeping the immune system alerted against cancer. Cancer Immunol Immunother 1998; 46:88-92.
25. Medina E, Guzman CA. Use of live bacterial vaccine vectors for antigen delivery: Potential and limitations. Vaccine 2001; 19:1573-80.
26. Pawelek JM, Low KW, Bermudes D. Bacteria as tumor-targeting vectors. Lancet Oncol 2003; 4:548-56.
27. Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr opinion pharmacol 2001; 1:364-9.
28. Onozawa C, Shimamura M, Iwasaki S, Oikawa T. Inhibition of angiogenesis by Rhizoxin, a microbial metabolite containing two epoxide groups. Jpn J Cancer Res 1997; 88:1125-9.
29. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motif in bacterial DNA tigger direct B cell activation. Nature 1995; 374:546-9.
30. Krieg AM. CpG motifs: The active ingredient in bacterial extracts? Nature Med 2003; 9:831-5.
31. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002; 168:1212-8.
32. Ribi EE, Granger DL, Milner KC, Strain SM. Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst 1975; 55:1253-7.
33. Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH, et al. Treatment of acute leukemia in adults. Cancer 1975; 36:775-95.
34. Reisser O, Pance A, Jeanin JF. Mechanism of anti-tumor effect of lipid A. Bioessays 2002; 24:284-9.
35. Keller R, Keist R, Joller P, Mulsch A. Coordinate up and down modulation of inducible nitric oxide synthase, nitric oxide production and tumoricidal activity in rat bone marrow derived mononuclear phagocytes by lipopolysaccharide and gram negative bacteria. Biochem Biophysic Res Commun 1995; 211:183-9.
36. Keller R, Keist R, Gustafson JE. Anti-tumor activity of bacteria and bacterial products: Enhancement of the tumor-protective effect of bacteria by lipoteichoic acid. Cancer Lett 1994; 82:99-104.
37. Mondal TK, Bhatta D, Biswas S, Pal P. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines and nitric oxide. Biochem Biophysic Res Commun 2002; 290:1336-42.
38. Altman KH, Wartmann M, O'Reilly T. Epothilones and related structures a new class of microtubule inhibitors with potent in vivo anti-tumor activity. Biochim et Biophys Acta 2000; 1470:78-91.
39. Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, et al. Desoxyepothilone B: An efficacious microtubule-targeted anti-tumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci 1998; 95:9642-7.
40. Chou TC, Oconnor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ, et al. The synthesis, discovery and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci 2001; 98:8113-8.
41. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations by desoxyepothilone B: Implications for drug-target interactions. Chem Biol 2003; 10:597-607.
42. Bodart JF, Chopra A, Liang X, Duesbery N. Anthrax, MEK and cancer. Cell Cycle 2002; 1:10-5.
43. Frank DW. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 1997; 26:621-9.
44. Hauser AR, Engel JN. Pseudomonas aeruginosa induces type III secretion mediated apoptosis of macrophages and epithelial cells. Infect Immun 1999; 67:5530-7.
45. Coburn J, Frank DW. Macrophages and epithelial cells respond differently to the Pseudomonas type III secretion system. Infect Immun 1999; 67:3151-4.
46. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci 2002; 99:14098-103.
47. Yamada T, Goto M, Punj V, Zaborina O, Kimbara K, Dasgupta TK, et al. The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53. Infect Immun 2002; 70:7054-62.
48. Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Das Gupta TK, et al. Induction of apoptosis in macrophages by Pseudomonas aeruginosa azurin: Tumor suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxiciy. Mol Microbiol 2003; 47:549-59.
49. Vousden KH, Lu X. Live or let die: The cells response to p53. Nat Rev Cancer 2002; 2:594-604.
50. Ryan KM, Vousden KH. Characterization of structural p53 mutants, which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18:3692-8.
51. Oren M. Decision making by p53: Life, death and cancer. Cell Death and Differ 2003; 10:431-42.
52. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small molecule antagonists of Mdm2. Science 2004; 303:844-8.
53. ARF in homeostatic tissues. Mol Cell Biol 2004; 24:186-91.
54. Lane DP, Fischer PM. Turning the key on p53. Nature 2004; 427:789-90.
55. Woods YL, Lane DP. Exploiting the p53 Pathway from cancer diagnosis and therapy. Hematol J 2003; 4:233-47.
56. Pearson S, Jia H. China approves first gene therapy. Nature Biotechnology 2004; 22:3-4.
57. Punj V, DasGupta TK, Chakrabarty AM. Bacterial redox protein azurin and its interactions with tumor suppressor protein p53. Biochem Biophys Res Communication 2003; 12:109-14.
58. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cummingham EA, Graves J, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004; 13:2363-74.
59. Yamada T, Yashinori H, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, et al. Apoptosis or growth arrest: Modulation of tumor suppressor specificity by bacterial redox protein azurin. Proc Natl Acad Sci 2004; 101:4770-5.
60. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577-90.
61. Punj V, Vasu C, Saint-Dic D, Chakrabarty AM, Das Gupta TK. Bacterial redox protein azurin as an anti-tumor agent: Mechanism of action, its bioavailability and immune response in mice. Clin Cancer Res 2003; 9:6251S.
62. Chen HM, Wang W, Smith D, Chen SC, et al. Effect of the anti-bacterial peptide cecropin B and its analogs, cecropinsB-1 and B-2, on liposomes, bacteria and cancer cells. Biochem Biophys Acta 1997; 1336:171-9.
63. Cruciani RA, Barker JL, Zaslof M, Chen HC, Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci 1991; 3792-6.
64. Moore AJ, Devine D, Bibby MC. Preliminary experimental anticancer activity of cecropins. Peptide Res 1994; 7:205-9.
65. Winder D, Gunzburg WH, Erfle V, Salmons B. Expression of anti-microbial peptides has an anti-tumor effect in human cells. Biochem Biophysic Res Commun 1998; 243:608-12.
66. Srisailam S, Arunkumar AI, Wang W, Yu C, Chen HM. Conformational study of a custom antibacterial peptide cecropin B1: Implication of the lytic activity. Biochem Biophysica Acta 2000; 1479:275-85.
67. Ben-Tal N, Honig B. Helix-helix interaction in lipid bilayers. Biophys J 1996; 71:3046-50.
68. Hristova K, Selsted ME, White SH. Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins. J Biol Chem 1997; 272:24224-33.
69. Philip PA, Flaherty LE. Bio-chemotherapy for melanoma. Current Oncol Report 2000; 2:314-21.
70. Punj V, Chakrabarty AM. Redox proteins in mammalian cell death: An evolutionarily conserved function in mitochondria and prokaryotes. Cell Microbiol 2003; 5:225-31.
71. Ikonen M, Liu B, Haskimoto Y, Ma L, Lee KW, Niikura T, et al. Interaction between the Alzheimers survival peptide humanin and insulin-like growth factor-binding protein regulates cell survival and apoptosis. Proc Natl Acad Sci 2003; 100:13042-7.